AvroBio Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
AVROBIO, Inc. is a leading, Phase 2 gene therapy company focused on the development of its investigational gene therapy, AVR-RD-01, in Fabry disease, as well as additional gene therapy programs in other lysosomal storage disorders including Gaucher disease, cystinosis and Pompe disease. The Company’s plato™ platform includes a proprietary vector system, automated cell manufacturing solution and refined conditioning regimen deploying therapeutic drug monitoring. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON.
Current Price
$28.53
-1.69%Profile
Valuation (TTM)
Market Cap$543.15M
P/E-7.32
EV—
P/B2.16
Shares Out19.04M
P/Sales—
Revenue$0.00
EV/EBITDA—
AvroBio Inc (TECX) Stock News
TECX Stock News & Headlines
Latest stock news and headlines for AvroBio Inc (TECX). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $28.53. Market cap: $543.15M. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to TECX from financial news sources, helping investors stay current on events that may impact AvroBio Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on AvroBio Inc (TECX).